MRFF Funding Opportunities

Several funding opportunities are currently available under the MRFF, seeking to address a range of different diseases and issues in different health settings. They are presented in order of application closing date below.

Want to assist with assessing MRFF grants?
The Department of Health is currently seeking interest from a range of stakeholders to assist in MRFF grant review and assessment as a member of a Grant Assessment Committee. More information is available here.

Open for application now

Clinical Trials

The Medical Research Future Fund (MRFF) CTA Initiative – 2021 Clinical Trials Activity grant opportunity aims to fund research projects with up to $3 million in two priority areas:

    • Rare cancers, rare diseases and unmet need. Applications to the Rare cancers, rare disease and unmet need priority are required to address a rare cancer, rare disease and/or an unmet need.
    • Effective health interventions.
      • Conduct a clinical trial of new drug and/or non-drug treatments and therapies in individuals who have been identified through molecular testing.
      • Conduct an implementation science trial to determine best ways to implement preventative health interventions, screening or diagnostic test, therapeutic agent, technology or model of care that is not in routine use in Australia.
      • Conduct a clinical trial assessing the comparative effectiveness and acceptability of health interventions in improving outcomes in individuals with complex chronic conditions, including comorbidities.

The grant opportunity is being administered by the NHMRC and minimum data is due on 22 June 2022.

Preventive and Public Health Research initiative – 2021 Consumer-Led Research Grant Opportunity

Grants of up to $1 million are available to:

    • Stream 1: projects that develop and/or test the implementation of interventions for improving:
      • health self-efficacy for consumers with long term diseases and conditions, and/or
      • health self-efficacy for priority populations (including culturally and linguistically diverse, Aboriginal and/or Torres Strait Islander and low socioeconomic status).
    • Stream 2: projects that use citizen science methodologies where citizens and scientists use web-based platforms and digital tools to co-create health knowledge that has practical implications for improving health outcomes and/or improving consumer experiences of health care, whilst increasing consumer understanding of, and consumer involvement in, research.

The grant opportunity is being administered by the NHMRC and minimum data is due on 29 June 2022. Guidelines are available on Grant Connect.

Preventive and Public Health Research – 2021 Maternal Health and Healthy Lifestyles Grant Opportunity

The objective of this grant opportunity is to provide grants of up to $2 million for projects that:

    • Stream 1: develop new scalable approaches to improve maternal and or early childhood nutrition and exercise
    • Stream 2: develop new scalable approaches to reduce alcohol and other drug use by adolescents and young adults
    • Stream 3: develop new co-designed and scalable lifestyle interventions to reduce the risk of cancer in priority populations.

The grant opportunity is being administered by the NHMRC and minimum data is due on 29 June 2022. Guidelines are available on Grant Connect.

 2021 Primary Health Care Digital Innovations Grant Opportunity

$5 million is available to projects that develop novel digital health tools and technologies to improve access to primary health care services in disadvantaged and/or vulnerable populations (for example, migrant communities, people living with disabilities, lower socioeconomic communities, and rural and regional Australia).

The grant opportunity is being administered by the NHMRC and minimum data is due on 29 June 2022. Guidelines are available on Grant Connect.

2021 Early to Mid-Career Researchers Grant Opportunity

The objective of the 2021 Early to Mid-Career Researchers Grant Opportunity is to provide grants of up to $5 million to support Australian medical research and medical innovation projects that:

    • Stream 1 (Incubator): conduct early stage, small-scale research, led by early-career researchers, that seeks to assess the potential and feasibility of novel strategies to address a critical or intractable health issue
    • Stream 2 (Accelerator): establish a large-scale interdisciplinary research program, led by mid-career researchers, that drives implementation of substantial improvements to health care and/or health system effectiveness
    • Stream 3 (Targeted Call for Research): utilise co-funding between the MRFF, a sponsoring academic organisation and partner organisation(s) to accelerate translation of research led by early to mid-career researchers.

An early-career researcher is defined as an individual who is within five years post PhD (i.e. within five years of their PhD conferral date), excluding career disruptions.  A mid-career researcher is defined as an individual who is between five and ten years post PhD (i.e. between five and ten years of their PhD conferral date), excluding career disruptions. 

The grant opportunity is being administered by the NHMRC and minimum data is due on 29 June 2022. Guidelines are available on Grant Connect.

Chronic Respiratory Conditions

The  PPHRI 2021 Chronic Respiratory Conditions Grant Opportunity will provide grants of up to $2million for:

    • Stream 1:  develop treatable trait-based precision medicine approaches for chronic respiratory disease
    • Stream 2: clinically validate feasible technology enabled approaches to medication and therapeutic adherence and self-management of chronic respiratory diseases.

The grant opportunity is being administered by the NHMRC and minimum data is due on 29 June 2022. Guidelines are available on Grant Connect.

mRNA Clinical Trial Enabling Infrastructure

The 2021 mRNA Clinical Trial Enabling Infrastructure grant opportunity will fund an organisation who has previously applied to the Department of Industry, Science, Energy and Resources (DISER) and Department of Health’s Approach To Market: Enabling Australia’s onshore mRNA manufacturing capability. In addition, they must specify at least one state government partner organisation contributing to the research.

The objective of this grant opportunity is to provide funding to Australian medical research and medical innovation projects that leverage and enhance emerging technologies, platforms, equipment and infrastructure to conduct clinical trials of mRNA-based vaccines and/or therapeutics. The intended outcome is to improve the health and wellbeing of Australians by accelerating the development of mRNA-based vaccines and treatments to address health challenges through enhancement of Australia’s clinical trials research infrastructure.

For this grant opportunity, up to $25 million is available over 3 years from 2022-23, with $15 million available in 2022-23. The maximum grant is $5 million.

Applications can be made through the Business Grants Hub, and close on 15 July. The Guidelines are available on Grant Connect here.

Physical Activity, Treatments and Therapies

A total of $13 million is available, with individual grants of up to $1.5 million for projects that:

Stream 1: develop  implement and/or validate scalable approaches for personalised exercise programs to maximise disease risk factor reduction and adherence in adults aged over 45 years who are not currently meeting physical activity guidelines.

Stream 2: develop  implement and/or validate approaches for effective community-led physical activity programs co-designed with a priority population.

Stream 3: develop  implement and/or validate approaches that use physical treatments and therapies to improve the quality of life of children and adolescents with childhood dementia  an umbrella term used to describe progressive neurological deterioration and mental impairment in children.

An application may only be submitted to one of the above three Streams only. Applicants must specify the Stream to which they are applying in their application. This grant opportunity is being administered by the NHMRC and minimum data is due on 13 July.  Grant guidelines are available here.

2022 International Clinical Trial Collaborations Grant Opportunity

A total of $12 million is available, with maximum grants of $3 million, over two separate rounds. Applications to this Grant Opportunity must propose a single clinical trial in Australia in collaboration with international counterparts which aims to:

    • give patients across Australia more access to clinical trials
    • show which treatments and medicines work best for patients
    • provide researchers with more opportunities to work with international colleagues to bring international trials to Australian patients
    • promote new approaches that support efficient and effective research.

This grant opportunity is being administered by the NHMRC over two rounds and minimum data is due on:

Round 1: 20 July 2022

Round 2:  8 February 2023

Grant guidelines are available here.

Clinician Researchers: Nurses  Midwives and Allied Health

A total of $20.3 million is available, with maximum grants of $1.5 million, for projects that:

Streams 1 and 2: support medical research projects led by nurses, midwives and allied health professionals that validate and implement new approaches for improving the quality of patient care.

Stream 3: prospectively evaluate projects funded through Streams 1 and 2 to generate knowledge that improves understanding of the factors that promote the adoption, impact and sustainability of evidence-based practice in health care.

This grant opportunity is being administered by the NHMRC and minimum data is due on 27 July.  Grant guidelines are available here.

Dementia  Ageing and Aged Care Grant Opportunity

A total of $24 million is available, with maximum grants of $2 million, for projects that:

Stream 1: develop interventions that deliver holistic and multidisciplinary care after diagnosis to improve quality of life for people living with dementia and their carers.

Stream 2: conduct implementation research focused on addressing inequalities in uptake of prevention activities to support healthy ageing and quality of life for:

    • Topic A: Aboriginal and Torres Strait Islander people
    • Topic B: Rural, regional and remote populations
    • Topic C: Culturally and linguistically diverse populations.

Stream 3: enhance utility of neuropsychological tests for dementia.

An application may only be submitted to one of the above three Streams only.  This grant opportunity is being administered by the NHMRC and minimum data is due on 24 August.  Grant guidelines are available here.

Brain Cancer Research Infrastructure

$6 million is available to support a national consortium that :

    • develops, enhances and integrates brain cancer research infrastructure platforms
    • enables and promotes new and improved research approaches and methodologies
    • enables and promotes accessibility and the ongoing use of the brain cancer research infrastructure by researchers and clinicians.

This grant opportunity is being administered by the NHMRC and minimum data is due on 24 August.  Grant guidelines are available here.

Cardiovascular Health

A total of $24 million is available, with maximum grants of $5 million, for projects that:

to provide grants of financial assistance to support Australian medical research and medical innovation projects that:

Stream 1 (Targeted Call for Research): improve the understanding of cardiovascular disease risk, including biological mechanisms.

Stream 2 (Targeted Call for Research): conduct preclinical development and validation of novel molecular targets and novel device approaches for cardiovascular disease and/or stroke.

Stream 3 (Accelerator): conduct a large-scale project focused on discovery and testing of new, broadly applicable (multiple disease groups) interventions for cardiovascular disease and/or stroke (e.g. anti-inflammatory targets).

An application may be submitted to one of the above three Streams only. This grant opportunity is being administered by the NHMRC and minimum data is due on 24 August. Grant guidelines are available here.

Stem Cell Therapies

A total of $10 million is available, with maximum grants of $1 million, for projects that:

Stream 1 : support short-term  small-scale development projects to establish the feasibility of novel cellular therapies.

Stream 2 : support short-term  small-scale projects that: develop and validate human stem-cell based models of disease  including genetic disease  infectious diseases and cancer develop high-content or high-throughput screening approaches  or generate patient-derived stem cell lines for screening treatments.

An application may be submitted to one of the above three Streams only. This grant opportunity is being administered by the NHMRC and minimum data is due on 24 August. Grant guidelines are available here.

Pancreatic Cancer

$12 million is available in grants of up to $2 million for research projects that:

Stream 1: develop, implement and/or validate therapeutic approaches (drug and/or non-drug) for improving the management of pain and symptoms in individuals with pancreatic cancer

Stream 2: promote Australian involvement in international collaborative investigator-initiated clinical trials testing the effectiveness of treatments (drug and/or non-drug) for pancreatic cancer through the establishment and coordination of clinical trials site/s in Australia.

This grant opportunity is being administered by the NHMRC over two rounds and minimum data is due on:

Round 1: 24 August

Round 2:  23 November

Grant guidelines are available here.

BioMedtech Incubator

The 2021 BioMedtech Incubator grant is part of the Medical Research Commercialisation Initiative. It will fund the most suitable organisation which can identify and select a number of Australian small and medium enterprises (SMEs) undertaking early-stage medical research and medical innovation projects that have commercial potential.

The successful organisation, in partnership with SMEs, aims to progress and support medical research and medical innovation projects by:

    • providing access to capital and industry knowledge
    • facilitating an environment where research projects are incubated
    • providing up to $5 million in funding for selected SMEs over 5 years to develop a research project.

Up to $50 million is available over two years; $35 million in 2022-23 and $15 million in 2023-24.

The selection of the Incubator will be managed by the Business Grants Hub and the application process closes on 25 August. The Guidelines are available on Grant Connect here.

2022 Mitochondrial Donation Pilot Program

Up to $15 million is available to support one research and innovation project for up to five years that conducts a pilot program, including a clinical trial, for the purposes of building the evidence base to determine the safety, efficacy and feasibility of implementing mitochondrial donation reproductive technology in clinical practice settings.

The intended outcomes are:

    • assisting women whose mitochondria would predispose their potential children to mitochondrial disease to have a biological child who does not inherit that predisposition
    • building a body of knowledge through research and ongoing monitoring of trial participants (including children born as a result of mitochondrial donation) to support future government policy decisions regarding broader implementation of mitochondrial donation reproductive technology in clinical practice in Australia.

This grant opportunity is being administered by the NHMRC and minimum data is due on 31 August. The guidelines are available on Grant Connect.

Multiple Sclerosis

$18 million is available for research projects that:

Stream 1: promote Australian involvement in international collaborative investigator-initiated clinical trials testing the effectiveness of vaccines for prevention of latent Epstein-Barr virus infection through the establishment and coordination of clinical trials site/s in Australia

Stream 2: clinical trials to accelerate the development or repurposing of therapeutic candidates (including antivirals) to treat Epstein-Barr virus for the purpose of preventing or treating conditions such as multiple sclerosis

Stream 3: characterise how immune responses to viral infections trigger autoimmune diseases including multiple sclerosis in some individuals to generate knowledge that supports risk stratification so identified individuals can employ strategies to reduce their chance of developing autoimmune disease

Stream 4: develop, implement and/or validate approaches for early intervention in individuals recovering from viral infections that aim to reduce the risk and/or severity of the long-term autoimmune consequences, including multiple sclerosis.

This grant opportunity is being administered by the NHMRC over two rounds and minimum data is due on:

Round 3 and 4: 16 November 2022

Round 1 and 2: 25 January 2023

Grant guidelines are available here.

Opening Soon

Medicine Use and Intervention by Pharmacists

Opening on 16 June, the 2022 Quality, Safety and Effectiveness of Medicine Use and Medicine program will fund organisations to undertake research to support innovative approaches to improve the quality and cost effectiveness of preventive healthcare interventions.  Applications to all Streams must be pharmacist-led; i.e. the Chief Investigator A (CIA) must be a pharmacist.

Stream 1: assess the feasibility (including cost effectiveness, and acceptability by patients and prescribing health professionals) of pharmacogenomic interventions by community pharmacists designed to optimise medication prescription and use

Stream 2: assess the feasibility (including cost effectiveness, scalability, and acceptability by patients and prescribing health professionals) of pharmacogenomic interventions to optimise the prescription and use of medicines for treating patients with cancer (oncology and supportive care)

Stream 3: implement, validate, and cost approaches that involve community and hospital pharmacists collaborating to improve medication management at transition into the community

Stream 4: implement, validate, and cost approaches for pharmacist interventions in residential aged care using objective patient focused indicators.

Up to $6.5 million is available in total, with applications to open on 16 June and close on 7 September. The grants will be administered by the Business Grants Hub.  The Guidelines are available on Grant Connect here.

 

2022 MRFF Joint Transnational Call

The European Joint Programme on Rare Diseases (EJP RD) brings over 130 institutions from 35 countries together to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation. 

As part of the EJP RD, international organisations have joined forces to carry out a joint call for proposals for transnational cooperative research projects in the field of rare diseases. The list of participating funding organisations is listed on the EJP RD website. 

The joint call is published at the same time by the funding organisations in the respective countries and coordinated centrally by a Joint Call Secretariat (JCS). The JCS is based at the Institute of Health Carlos III (ISCIII, Spain). The respective national guidelines apply to the actual implementation of the national sub-projects. 

The applications will open in December 2022 and will be administered by the NHMRC. The maximum grant is $300,000. The Guidelines are available on Grant Connect here.